Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
0(0%)
Results Posted
33%(4 trials)

Phase Distribution

Ph phase_2
2
17%
Ph phase_4
5
42%
Ph phase_3
4
33%

Phase Distribution

0

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
4(36.4%)
Phase 4Post-market surveillance
5(45.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(12)

Detailed Status

Completed12

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (18.2%)
Phase 34 (36.4%)
Phase 45 (45.5%)

Trials by Status

completed12100%

Recent Activity

0 active trials
Showing 5 of 12
completed

Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness

NCT02843685
completedphase_3

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

NCT00604214
completedphase_2

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

NCT00386425
completedphase_4

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

NCT00279214
completedphase_2

Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study

NCT00191724
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02843685

Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness

Completed
NCT00604214Phase 3

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Completed
NCT00386425Phase 2

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Completed
NCT00279214Phase 4

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

Completed
NCT00191724Phase 2

Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study

Completed
NCT00067730Phase 4

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

Completed
NCT00568737Phase 3

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

Completed
NCT00568893Phase 4

An Open Label Study of Severe Sepsis in Adults

Completed
NCT00049764Phase 3

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis

Completed
NCT00190788Phase 3

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

Completed
NCT00049777Phase 4

A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

Completed
NCT00045760Phase 4

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12